Display options
Cite
Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry. 2011;2:64doi: 10.3389/fpsyt.2011.00064.
Diana, M. (2011). The dopamine hypothesis of drug addiction and its potential therapeutic value. Frontiers in psychiatry, 264. https://doi.org/10.3389/fpsyt.2011.00064
Diana, Marco. "The dopamine hypothesis of drug addiction and its potential therapeutic value." Frontiers in psychiatry vol. 2 (2011): 64. doi: https://doi.org/10.3389/fpsyt.2011.00064
Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry. 2011 Nov 29;2:64. doi: 10.3389/fpsyt.2011.00064. eCollection 2011. PMID: 22144966; PMCID: PMC3225760.
Copy Download .nbib Format: NLM
Share it on

Front Psychiatry. 2011 Nov 29;2:64. doi: 10.3389/fpsyt.2011.00064. eCollection 2011.

The dopamine hypothesis of drug addiction and its potential therapeutic value.

Frontiers in psychiatry

Marco Diana

Affiliations

  1. 'G. Minardi' Cognitive Neuroscience Laboratory, Department of Drug Sciences, University of Sassari Sassari, Italy.

PMID: 22144966 PMCID: PMC3225760 DOI: 10.3389/fpsyt.2011.00064

Abstract

Dopamine (DA) transmission is deeply affected by drugs of abuse, and alterations in DA function are involved in the various phases of drug addiction and potentially exploitable therapeutically. In particular, basic studies have documented a reduction in the electrophysiological activity of DA neurons in alcohol, opiate, cannabinoid, and other drug-dependent rats. Further, DA release in the Nucleus accumbens (Nacc) is decreased in virtually all drug-dependent rodents. In parallel, these studies are supported by increments in intracranial self stimulation (ICSS) thresholds during withdrawal from alcohol, nicotine, opiates, and other drugs of abuse, thereby suggesting a hypofunction of the neural substrate of ICSS. Accordingly, morphological evaluations fed into realistic computational analysis of the medium spiny neuron of the Nacc, post-synaptic counterpart of DA terminals, show profound changes in structure and function of the entire mesolimbic system. In line with these findings, human imaging studies have shown a reduction of dopamine receptors accompanied by a lesser release of endogenous DA in the ventral striatum of cocaine, heroin, and alcohol-dependent subjects, thereby offering visual proof of the "dopamine-impoverished" addicted human brain. The lasting reduction in physiological activity of the DA system leads to the idea that an increment in its activity, to restore pre-drug levels, may yield significant clinical improvements (reduction of craving, relapse, and drug-seeking/taking). In theory, it may be achieved pharmacologically and/or with novel interventions such as transcranial magnetic stimulation (TMS). Its anatomo-physiological rationale as a possible therapeutic aid in alcoholics and other addicts will be described and proposed as a theoretical framework to be subjected to experimental testing in human addicts.

Keywords: VTA; addiction; dopamine; dopamine agents; prefrontal cortex; rTMS

References

  1. Trends Neurosci. 2006 Nov;29(11):610-6 - PubMed
  2. Pharmacol Ther. 1987;35(1-2):227-63 - PubMed
  3. Synapse. 2003 Sep 15;49(4):226-31 - PubMed
  4. Curr Drug Abuse Rev. 2008 Nov;1(3):328-39 - PubMed
  5. Alcohol Clin Exp Res. 1996 Dec;20(9):1594-8 - PubMed
  6. J Psychiatr Res. 2005 May;39(3):295-302 - PubMed
  7. Addiction. 2009 Apr;104(4):653-60 - PubMed
  8. J Neurosci. 2011 Jul 6;31(27):9885-94 - PubMed
  9. Exp Neurol. 2009 Sep;219(1):2-13 - PubMed
  10. Curr Pharm Des. 2010;16(19):2136-40 - PubMed
  11. J Neurophysiol. 2008 May;99(5):2725-30 - PubMed
  12. Neurosci Biobehav Rev. 2010 Mar;34(4):559-74 - PubMed
  13. Brain Struct Funct. 2008 Sep;213(1-2):17-27 - PubMed
  14. Neurosci Lett. 1993 Jul 9;157(1):53-6 - PubMed
  15. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5880-4 - PubMed
  16. Curr Pharm Des. 2010;16(19):2159-18 - PubMed
  17. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):586-91 - PubMed
  18. Biol Psychiatry. 2010 Oct 15;68(8):689-96 - PubMed
  19. Neuroreport. 2007 Feb 12;18(3):289-92 - PubMed
  20. Am J Psychiatry. 2009 Oct;166(10):1170-7 - PubMed
  21. Brain Topogr. 2008 Sep;21(1):1-10 - PubMed
  22. Addiction. 1997 Aug;92(8):969-78 - PubMed
  23. Addict Biol. 2010 Jul;15(3):266-76 - PubMed
  24. Clin Neurophysiol. 2008 Mar;119(3):667-674 - PubMed
  25. J Neurochem. 1995 Sep;65(3):1407-10 - PubMed
  26. Eur J Neurosci. 2001 Jul;14(1):96-102 - PubMed
  27. JAMA. 2009 Jan 14;301(2):183-90 - PubMed
  28. J Neurosci. 2000 May 15;20(10):3864-73 - PubMed
  29. J Neurosci. 2006 May 31;26(22):5894-900 - PubMed
  30. Eur J Neurosci. 2003 Feb;17(3):605-12 - PubMed
  31. Neuropsychopharmacology. 2006 Aug;31(8):1627-36 - PubMed
  32. Neuropharmacology. 2001 Dec;41(8):989-99 - PubMed
  33. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7966-9 - PubMed
  34. Lancet Neurol. 2003 Mar;2(3):145-56 - PubMed
  35. J Neurosci. 2007 Nov 14;27(46):12700-6 - PubMed
  36. Addiction. 2010 Jan;105(1):49-55 - PubMed
  37. J Neurochem. 2001 Sep;78(5):1094-103 - PubMed
  38. J Neurochem. 1996 Feb;66(2):589-98 - PubMed
  39. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8 - PubMed
  40. J Clin Psychopharmacol. 2010 Aug;30(4):365-72 - PubMed
  41. J Neurosci. 1997 Nov 1;17(21):8491-7 - PubMed
  42. Neuropsychopharmacology. 2010 Jan;35(1):217-38 - PubMed
  43. J Psychopharmacol. 2009 Mar;23(2):123-9 - PubMed
  44. Alcohol Clin Exp Res. 1992 Jun;16(3):529-32 - PubMed
  45. Trends Neurosci. 2010 Jun;33(6):267-76 - PubMed
  46. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(2):195-214 - PubMed
  47. Am J Bioeth. 2007 Jan;7(1):8-11 - PubMed
  48. Int Rev Neurobiol. 2005;63:101-54 - PubMed
  49. Neuropharmacology. 1995 Jul;34(7):785-91 - PubMed
  50. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11202-7 - PubMed
  51. Neuroscience. 1996 Mar;71(2):411-5 - PubMed
  52. Biol Psychiatry. 2005 Nov 15;58(10):779-86 - PubMed
  53. Neuropsychopharmacology. 2008 Sep;33(10):2517-23 - PubMed
  54. Neuropharmacology. 2002 Jul;43(1):101-9 - PubMed
  55. Ann N Y Acad Sci. 2006 Aug;1074:446-57 - PubMed
  56. Behav Neurosci. 1993 Dec;107(6):1077-87 - PubMed
  57. Neuroscience. 1988 Jan;24(1):19-28 - PubMed
  58. J Neurosci. 2001 Aug 1;21(15):RC157 - PubMed
  59. Drug Alcohol Rev. 2010 May;29(3):235-42 - PubMed
  60. Pharmacol Biochem Behav. 1980;13 Suppl 1:213-23 - PubMed
  61. Neuropharmacology. 2004;47 Suppl 1:33-46 - PubMed
  62. Nat Rev Drug Discov. 2009 Jun;8(6):500-15 - PubMed
  63. Neuropsychopharmacology. 2003 Aug;28(8):1400-11 - PubMed
  64. Nat Neurosci. 2005 Nov;8(11):1431-6 - PubMed
  65. Eur J Neurosci. 1999 Mar;11(3):1037-41 - PubMed
  66. Nat Med. 1995 Apr;1(4):337-41 - PubMed
  67. Alcohol Clin Exp Res. 2008 Nov;32(11):1954-61 - PubMed
  68. Biol Psychiatry. 2001 Feb 15;49(4):369-73 - PubMed
  69. Alcohol Clin Exp Res. 2003 Feb;27(2):354-61 - PubMed
  70. Alcohol Clin Exp Res. 2008 Apr;32(4):573-9 - PubMed
  71. Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):91-8 - PubMed
  72. Neuropsychopharmacology. 2004 Nov;29(11):2074-80 - PubMed
  73. Neuroreport. 2002 Dec 20;13(18):2401-5 - PubMed
  74. Alcohol Clin Exp Res. 2004 May;28(5):720-8 - PubMed
  75. J Clin Psychopharmacol. 2008 Feb;28(1):5-12 - PubMed
  76. Arch Gen Psychiatry. 2006 Sep;63(9):999-1008 - PubMed
  77. Neuroimaging Clin N Am. 2007 Nov;17(4):539-55, x - PubMed
  78. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10269-73 - PubMed
  79. Hum Psychopharmacol. 2009 Aug;24(6):465-72 - PubMed
  80. J Neurochem. 1992 Apr;58(4):1491-8 - PubMed
  81. Eur J Neurosci. 2005 Nov;22(9):2332-40 - PubMed
  82. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9 - PubMed
  83. Brain Res. 1988 Oct 11;462(1):194-8 - PubMed
  84. J Neurosci. 1996 May 15;16(10):3474-85 - PubMed
  85. Am J Addict. 2008 Jul-Aug;17(4):345-6 - PubMed

Publication Types